Related Experiment Video

Updated: Jul 2, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives]

S Oudard1, J-N Cornu, M Rouprêt

  • 1HEGP, Oncologie médicale, AP-HP, 20, rue Leblanc, GHU Ouest, 75908 PARIS cedex 15, Faculté René Descartes, Paris 5, France. stephane.oudard@egp.aphp.fr

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|September 26, 2008
PubMed

Insights

Anti-angiogenic agents are revolutionizing metastatic renal cell carcinoma treatment. Ongoing trials explore their use alongside or instead of surgery, improving patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Metastatic renal cell carcinoma (mRCC) treatment has been significantly altered by anti-angiogenic agents.
  • Established drugs include sunitinib, sorafenib, temsirolimus, and bevacizumab.
  • Current research focuses on optimizing these therapies.

Purpose:

  • To review the evolving role of anti-angiogenic agents in mRCC management.
  • To discuss the potential integration of these agents into adjuvant settings and as alternatives to radical nephrectomy.

Summary:

  • Clinical trials are investigating ways to enhance the effectiveness, survival rates, response criteria, and toxicity profiles of existing anti-angiogenic drugs.
  • Emerging data suggest these therapies may be used adjuvantly after nephrectomy or as a primary treatment, challenging the traditional role of surgery.
  • Future mRCC management will likely involve increased patient participation in clinical trials for personalized anti-angiogenic therapy.

Impact:

  • The findings suggest a paradigm shift in mRCC treatment, moving away from routine radical surgery towards more targeted anti-angiogenic therapies.
  • This approach aims to improve patient survival and quality of life through optimized therapeutic strategies.
  • Encouraging patient enrollment in clinical trials is crucial for advancing the effective management of mRCC.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...